| Identification | Back Directory | [Name]
2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]- | [CAS]
2370013-12-8 | [Synonyms]
Sunvozertinib
2-Propenamide, N-[5-[[4-[[5-chloro-4-fluoro-2-(1-hydroxy-1-methylethyl)phenyl]amino]-2-pyrimidinyl]amino]-2-[(3R)-3-(dimethylamino)-1-pyrrolidinyl]-4-methoxyphenyl]- | [Molecular Formula]
C29H35ClFN7O3 | [MOL File]
2370013-12-8.mol | [Molecular Weight]
584.08 |
| Chemical Properties | Back Directory | [density ]
1.35±0.1 g/cm3(Predicted) | [storage temp. ]
Store at -20°C | [form ]
Solid | [pka]
12.29±0.70(Predicted) | [color ]
Off-white to light brown |
| Hazard Information | Back Directory | [Uses]
Sunvozertinib (DZD9008) is a potent ErbBs (EGFR, Her2, especially mutant forms) and BTK inhibitor. Sunvozertinib shows IC50s of 20.4, 20.4, 1.1, 7.5, and 80.4 nM for EGFR exon 20 NPH insertion, EGFR exon 20 ASV insertion, EGFR L858R and T790M mutations, and Her2 Exon20 YVMA, and EGFR WT A431, respectively (patent WO2019149164A1, example 52)[1]. | [IC 50]
EGFR exon 20 insertion: 20.4 nM (IC50); EGFRL858R/T790M: 1.1 nM (IC50); Her2 Exon20 YVMA: 7.5 nM (IC50) | [References]
[1] Zhengtao LI, et al. Erbb/btk inhibitors. WO2019149164A1. |
|
|